Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Pfizer
Woman
Between 18 years
and 99 years
Pfizer
Update Il y a 5 ans
PALOMA-2 : Essai de phase 3 randomisé, en double-aveugle, évaluant l’efficacité du palbociclib (PD-0332991) associé à du létrozole, chez des patientes ménopausées ayant un cancer du sein RE+/HER2- non traité. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité du palbociclib (PD-0332991) associé à du létrozole, chez des patientes ménopausées ayant un cancer du sein RE+/HER2-. Les patientes seront réparties...
Country
France
organs
Sein
Specialty
Thérapies Ciblées
,
Hormonothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Pfizer Inc.235 East 42nd Street, New York, NY 10017
Update Il y a 5 ans
A study to find out how long a person continues to have antibodies against Meningococcal B disease following vaccination
To describe the immunogenicity of bivalent rLP2086 as determined by hSBA titers to primary test strains at approximately 6, 12, 18, 24, 36, and 48 months after the last dose (second or third dose) of ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc. NYO-685-21-14,685 3rd Avenue, NEW YORK, NY 10017. US
Update Il y a 5 ans
12-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE IN COMPARISON TO TOLTERODINE ER IN PATIENTS WITH OVERACTIVE BLADDER
To compare the efficacy of fesoterodine to placebo and tolterodine ER in subjects with overactive bladder after 12 weeks of treatment.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc. 235 East 42nd Street, New York, 10017
Update Il y a 5 ans
A PHASE 3, MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
• To compare the efficacy of CP-690,550 (5 mg BID and 10 mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks of treatment in subjects with moderate to severe chroni...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc.235 East 42nd Street, New York, NY 10017
Update Il y a 5 ans
A STUDY OF THE MAINTENANCE OF EFFICACY OF ETANERCEPT PLUS DMARD(S) COMPARED WITH DMARD(S) ALONE IN SUBJECTS WITH RHEUMATOID ARTHRITIS AFTER ACHIEVING AN ADEQUATE RESPONSE WITH ETANERCEPT PLUS DMARD(S) VIZSGÁLAT AZ ETANERCEPT PLUSZ DMARD(OK) ÉS AZ ÖNMAGUKBAN ALKALMAZOTT DMARD(OK) FENNTARTOTT HATÁSOSSÁGÁNAK ÉRTÉKELÉSÉRE RHEUMATOID ARTHRITISBEN SZENVEDŐ BETEGEKNÉL, AKIK MEGFELELŐEN REAGÁLTAK AZ ETANERCEPT PLUSZ DMARD KEZELÉSRE
To compare the maintenance of efficacy of the combination of ETN 50 mg once weekly plus MTX (± other DMARDs) therapy with that of MTX (± other DMARDs) at Week 52 in subjects with moderately to severel...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Limited, Ramsgate Road, Sandwich, Kent, UK
Update Il y a 5 ans
A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF MONOTHERAPY SITAXSENTAN SODIUM VERSUS COMBINATION THERAPY WITH SITAXSENTAN SODIUM AND SILDENAFIL CITRATE IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION WHO HAVE COMPLETED STUDY B1321001
The primary objective of this study is to evaluate the efficacy of sitaxsentan (100 mg once daily) plus sildenafil (20 mg TID) as compared to sitaxsentan monotherapy by determining time to clinical wo...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc.235 East 42nd Street, New York, NY 10017
Update Il y a 5 ans
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS)
To characterize the dose response for tanezumab when administered by SC injection at an 8-weekly interval (2 injections) for moderate to severe chronic pain associated with (IC/PBS). To evaluate the...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc
Update Il y a 5 ans
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL AXITINIB (AG 013736) COME TRATTAMENTO DI SECONDA LINEA PER L'ADENOCARCINOMA RENALE METASTATICO (AXIS)
Compare the Progression-Free Survival (PFS) of patients with mRCC receiving AG-013736 (axitinib) vs sorafenib following failure of one prior systemic first-line regimen containing one or more of the...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc., 235 East 42nd Street, New York, NY 110017
Update Il y a 5 ans
PHASE 1 SAFETY AND TOLERABILITY STUDY OF FIGITUMUMAB COMBINED WITH PEGVISOMANT IN PATIENTS WITH ADVANCED SOLID TUMORS
To evaluate the safety and tolerability of figitumumab plus pegvisomant in patients with advanced solid tumors.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc.235 East 42nd Street, New York, NY 10017
Update Il y a 5 ans
PILOT STUDY OF NOVEL COMBINATION OF MARAVIROC +ATAZANAVIR/RITONAVIR VS ATAZANAVIR/RITONAVIR +EMTRICITABINE/TENOFOVIR FOR THE TREATMENT OF TREATMENT NAÏVE HIV-INFECTED PATIENTS WITH R5 HIV-1
To examine if the combination of maraviroc (SelzentryTM, Celsentri®) and atazanavir/ritonavir is effective for the treatment of treatment-naïve HIV-1 infected subjects as measured by the percentage of...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
19
20
21
22
23
24
25
26
27
28
Next